Firms
Theme

NUTX

Nutex Health Inc. · NASDAQ

News

3 latest

Zacks Investment Research

Bet on These 4 Stocks With Strong Net Profit Margins to Boost Returns

Four stocks—Nutex Health (NUTX), RCM Technologies (RCMT), Interface (TILE), and Quad/Graphics (QUAD)—were selected based on strong net profit margins, solid EPS growth outlooks, and positive analyst ratings. All four stocks carry Zacks Rank 1 or 2 ratings and VGM Scores of A or B, with recent upward earnings estimate revisions over the past 60 days.

Mentions NUTX

The Motley Fool

2 Stocks to Buy Hand Over Fist in October

Nutex Health and Elevance Health are recommended as undervalued healthcare stocks despite strong year-to-date performance. Nutex, a small-cap hospital operator, trades at less than 9x trailing earnings with exceptional EPS growth of 2,785% year-over-year. Elevance, a major health insurer, trades at a forward P/E of 14.52 below its five-year average, with consistent dividend increases and strong earnings guidance for 2026-2027.

Zacks Investment Research

5 Stocks With Recent Price Strength After a Mixed September

Five stocks have demonstrated significant price strength and improved earnings estimates following a mixed September market performance. Vince Holding, Vera Bradley, American Outdoor Brands, Nutex Health, and Forum Energy Technologies were identified using screening criteria including positive 4-week price momentum, Zacks Rank #1 ratings, and trading near 52-week highs. All five companies show expected earnings growth exceeding 60% for their current fiscal years.

Headlines link to the publisher. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $NUTX · 0 threads

Sign in to post on $NUTX

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev